These antibodies perform exceptionally well in the intended applications and have undergone stringent testing and additional validation to ensure monospecificity.
Trial Size Available
Carrier-Free Available
Formalin-fixed, paraffin-embedded human Renal Cell Carcinoma stained with Occludin Mouse Monoclonal Antibody (OCLN/2181).
Formalin-fixed, paraffin-embedded human thyroid carcinoma stained with Occludin Mouse Monoclonal Antibody (OCLN/2181).
Western Blot Analysis of MCF-7 cell lysate with Occludin Mouse Monoclonal Antibody (OCLN/2181).
SDS-PAGE Analysis of Purified Occludin Mouse Monoclonal Antibody (OCLN/2181). Confirmation of Purity and Integrity of Antibody.
Western Blot Analysis of human kidney tissue lysate using Occludin Mouse Monoclonal Antibody (OCLN/2181).
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol | Note |
|---|---|---|---|
| Immunohistochemistry (IHC) | 1-2ug/ml | IHC Protocol | 30 min at RT. Staining of formalin-fixed tissues requires heating tissue sections in 10mM Tris with 1mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes |
| Western Blot (WB) | 2-4ug/ml | Western Blot Protocol |
1
5
2
3
6
3
Occludin is a tetraspan integral membrane protein in epithelial and endothelial tight junction (TJ) structures that can contain two extracellular loops. The protein exists in a variety of phosphorylated forms. Phosphorylation is involved in regulating both the localization and the function of Occludin. Expression of Occludin is upregulated by polyunsaturated fatty acids, increasing trans-endothelial cell resistance and reducing cellular permeability to large molecules. The level of Occludin varies greatly depending on tissue; in brain tissue, Occludin is highly expressed at cell-cell contact sites. Non-neural tissues show lower expression and discontinuous distribution. Occludin is a tight junction protein that is a key structural component of the blood-brain barrier (BBB). Degradation of Occludin is frequently seen in ischemic stroke and contributes to BBB disruption.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time
